A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer

British Journal of Cancer

Volumn 105, Issue 1, 2011, Pages 13-17

  Glover, J A ^a   Hughes, C M ^b   Cantwell, M M ^b   Murray, L J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

breast cancer; COX 2; Cyclooxygenase 2; DCIS; MICB; review

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR;

BREAST CARCINOMA; BREAST EPITHELIUM; CANCER INVASION; CARCINOGENESIS; EMBASE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MEDLINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLOOXYGENASE 2; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959699548     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.204     Document Type: Review

References (32)

1. Abcam plc (1998-2010) http://www.abcam.com/index.html?pageconfig / resource&rid /11269&pid/1128. Accessed 29 December 2010
2. Bianchi S, Vezzosi V (2008) Microinvasive carcinoma of the breast. Pathol Oncol Res 14: 105-111
3. Blair CK, Sweeney C, Anderson KE, Folsom AR (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101: 191-197 (Pubitemid 46115425)
4. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90: 423-429 (Pubitemid 38250640)
5. Cho MH, Yoon JH, Jaegal YJ, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Lee MC, Park CS, Woo Juhng S, Min KW (2006) Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast 15: 390-398 (Pubitemid 43812216)
6. Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M, Schluns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G (2009) Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 11: R69
7. de la Torre J, Sabadell MD, Rojo F, Lirola JL, Salicru S, Reventos J, Cajal SR, Xercavins J (2010) Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome. Eur J Obstet Gynecol Reprod Biol 151: 72-76
8. Denkert C, Winzer KJ, Hauptmann S (2004) Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 4: 428-433 (Pubitemid 38443466)
9. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97: 2978-2987 (Pubitemid 36676251)
10. Gunnarsson C, Jansson A, Holmlund B, Ferraud L, Nordenskjold B, Rutqvist LE, Skoog L, Stal O (2006) Expression of COX-2 and steroid converting enzymes in breast cancer. Oncol Rep 16: 219-224
11. Haffty BG, Yang Q, Moran MS, Tan AR, Reiss M (2008) Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 71: 1006-1013
12. Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemo-prevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67
13. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472
14. Howe LR (2007) Inflammation and breast cancer. Cyclooxygenase/ prostaglandin signaling and breast cancer. Breast Cancer Res 9: 210
15. Imada T, Matsuoka J, Nobuhisa T, Okawa T, Murata T, Tabuchi Y, Shirakawa Y, Ohara N, Gunduz M, Nagatsuka H, Umeoka T, Yamamoto Y, Nakajima M, Tanaka N, Naomoto Y (2006) COX-2 induction by heparanase in the progression of breast cancer. Int J Mol Med 17: 221-228
16. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102: 627-637
17. Kulkarni S, Patil DB, Diaz LK, Wiley EL, Morrow M, Khan SA (2008) COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer 8: 36
18. Kwan ML, Habel LA, Slattery ML, Caan B (2007) NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18: 613-620 (Pubitemid 46883678)
19. Leo C, Faber S, Hentschel B, Hockel M, Horn LC (2006) The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol 10: 327-332 (Pubitemid 44765274)
20. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C (2005) COX-2 expression in DCIS: Correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histo-pathology 46: 561-568 (Pubitemid 40632313)
21. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cycloox-ygenase-2 expression in breast cancer. Cancer Res 62: 632-635 (Pubitemid 34126931)
22. Schmitz KJ, Callies R, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee HS, Takeda A, Schmid KW, Baba HA (2006) Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol 59: 685-691 (Pubitemid 44048775)
23. Singh B, Lucci A (2002) Role of cyclooxygenase-2 in breast cancer. J Surg Res 108: 173-179 (Pubitemid 35373830)
24. Singh-Ranger G, Salhab M, Mokbel K (2008) The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109: 189-198 (Pubitemid 351644840)
25. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T (2005) Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89: 215-220 (Pubitemid 43293067)
26. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P (2003) Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88: 574-578 (Pubitemid 36363367)
27. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M, Lage H (2005) Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res 7: R862-R870
28. Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100: 1439-1447
29. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM (2004) Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45: 47-54 (Pubitemid 38969561)
30. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, Rody A, Greb RR, Bocker W, Kiesel L (2003) Analysis of cyclooxygenase-2 expression in human breast cancer: High throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382 (Pubitemid 36995136)
31. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H (2008) Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 110: 465-475 (Pubitemid 351962589)
32. Zhao X, Goswami M, Pokhriyal N, Ma H, Du H, Yao J, Victor TA, Polyak K, Sturgis CD, Band H, Band V (2008) Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res 68: 467-475 (Pubitemid 351380073)